Nanoparticulate in-situ gels of TPGS, gellan and PVA as vitreous humor substitutes
View Patent ↗The present technology provides a nanoparticulate in-situ gelling vitreous substitute, which is a liquid at room temperature to aid easy administration, such as e.g. through a small needle incision, and forms a gel within the eye, which is hydrophilic in nature, similar to the natural vitreous. The vitreous substitute formulation may include a water-soluble natural or synthetic polymer and a gelling-agent which are blended together in the presence of a cross linker, to form a gel having the properties of the vitreous humor. The process of cross linking and gelation may occur in-situ. This can be achieved by dispensing to the eye, different components of the vitreous substitute in liquid state, along with the cross linking agent.
1. A vitreous substitute comprising
α-tocopheryl polyethylene glycol succinate (TPGS) and a polymeric blend of gellan and polyvinyl alcohol (PVA).
2. The vitreous substitute of claim 1 , wherein the polymeric blend comprises PVA and gellan in a ratio of from about 2:1 (w/w) to about 8:1 (w/w).
3. The vitreous substitute of claim 1 , wherein the polymeric blend is present at a final concentration from about 3% to about 7% by weight.
4. The vitreous substitute of claim 1 , wherein the TPGS is present at a final concentration from about 1 to about 2 mg/mL.
5. The vitreous substitute of claim 1 further comprising drug-loaded nanoparticles.
6. The vitreous substitute of claim 5 , wherein the drug-loaded nanoparticles are chitosan nanoparticles.
7. The vitreous substitute of claim 6 , wherein the chitosan nanoparticles contain from about 10 μg/mL to about 100 μg/mL of the drug.
8. The vitreous substitute of claim 5 , wherein the drug is selected from the group consisting of an antibiotic, an antioxidant, and an anti-vascularization agent.
9. The vitreous substitute of claim 8 , wherein the antibiotic is ciprofloxacin hydrochloride.
10. The vitreous substitute of claim 8 , wherein the anti-vascularization agent is an anti-VEGF antibody.
11. The vitreous substitute of claim 6 , wherein the chitosan nanoparticles are present at a concentration from about 0.1 mg/mL to about 1 mg/mL.
12. A method for at least partially replacing the vitreous of a subject, the method comprising:
administering to the vitreous cavity of an eye of the subject an effective amount of the liquid vitreous substitute of claim 1 ; and
administering to the vitreous cavity of the eye of the subject an effective amount of a cross-linker, wherein the liquid vitreous substitute forms a gel in the vitreous cavity.
13. The method of claim 12 , wherein the cross-linker comprises divalent cations.
14. The method of claim 12 , wherein the cross-linker is a calcium chloride solution.
15. A method for making a liquid vitreous substitute, the method comprising:
heating gellan and water to a temperature of about 80° C. to about 90° C. to form a gellan solution;
adding polyvinyl alcohol (PVA) to the gellan solution;
cooling the solution to a temperature of about 35° to about 55° C.;
adding α-tocopheryl polyethylene glycol succinate (TPGS) to the solution;
stirring the solution until the TPGS is completely dissolved and a clear liquid vitreous substitute solution is obtained.
16. The method of claim 15 further comprising adding a nanoparticle suspension to the solution after it has been cooled to a temperature of about 35° to about 55° C.
17. The method of claim 15 , wherein the PVA and gellan are added in a ratio of about 2:1 (w/w) to about 8:1 (w/w).
18. The method of claim 17 , wherein the total amount of PVA and gellan in the solution is from about 3% to about 7% by weight.
19. A kit for making a liquid vitreous substitute, the kit comprising: α-tocopheryl polyethylene glycol succinate (TPGS), gellan, polyvinyl alcohol (PVA), and a cross-linker.
20. The kit of claim 19 , wherein the cross-linker is calcium chloride.